1. Types of Publications
2. Peer Review Process
3. Publication Frequency
4. Open Access Policy
5. Core Editorial Policies
6. Publishing Ethics
7. Preprint Policy
8. Authorship and Author Information
12. Human Research
13. Patient Anonymity and Privacy
14. Animal Research
1. Types of Publications
Original research article
An original research article is based on original, basic and applied research and/or analysis. This type of article aims to describe significant and novel research. Authors of original research articles must confirm that the essential findings presented have never been published or under consideration elsewhere.
This article type typically has at least 5 tables and/or figures in total, approximately 40 references, and 7,000 words (inclusive of Abstract and References).
A review article provides scholarly survey as well as balanced summarization and highlights of recent developments in a research field or emerging/future trends. Authors should ensure that all perspectives from different works are linked in balanced and cohesive manner, taking into consideration different schools of thought.
This article type typically has at least 5 tables and/or figures in total, approximately 70 references, and 7,000 words (inclusive of Abstract and References).
A perspective article contains the author's scholarly opinions on a particular subject area or topic. Unlike a review, a perspective article covers a more specific part of the field, aiming to provide new insights into the subject matter. However, these perspectives or opinions should be objective in line with the spirit of academia. A good perspective piece should stimulate further discussions and initiate novel experiments.
This article type typically has 5 tables and/or figures in total, approximately 70 references, and 7,000 words (inclusive of Abstract and References).
This article type is a collection of unsolicited letters from the readers who wish to comment on specific articles published in Tumor Discovery or another field-related journal. Alternatively, a letter can be written on an unrelated topic of interest to the journal’s readership.
Ideally, a letter should present an in-depth, scholarly re-analysis of a previously published article in Tumor Discovery or in another field-related journal, accompanied by the reader’s constructive insights and comments. Letters containing new ideas, supporting data or data criticizing the indicated article may be subjected to peer review at editors’ discretion. Authors should specify the intended recipient of the letters, i.e., Editor or specific author(s).
This article type typically has no more than 3 tables and/or figures in total, no more than 20 references, and 2,000 words (inclusive of References). No Abstract is required.
An editorial piece is a solicited, concise commentary that highlights prominent topics in particular issue. Alternatively, an editorial represents the official opinions of the editors on the journal or special issue.
An editorial piece should not exceed 1,000 words (inclusive of References). An Abstract is not required. Only 1 figure or table is allowed.
An erratum is a notification of a significant error made by the editors that affects the scholarly record or the scientific integrity of a published article. An erratum is always accompanied by Publisher Correction of the error. The corrections will not be made directly in the already-published articles. Authors who notice an error in their published articles should contact the editors at email@example.com.
All publisher-introduced changes will be highlighted to the author for proofreading before final publication of the erratum.
A corrigendum is a notification of an important error made by the author(s) that affects the scholarly record or the scientific integrity of a published article. A corrigendum is always accompanied by Author Correction of the error. The corrections will not be made directly in the already-published articles.
If certain errors are found, author(s) should contact the editors at firstname.lastname@example.org, who will evaluate the impact of the errors and decide on the appropriate course of action. The publication of any corrections to a paper is at the sole discretion of the editors.
An addendum is a notification of additional information about a published article. An addendum will only be published if the editors decide that the additional information is essential to the reader’s understanding of a significant part of the published article. The additional information can be construed as description, information, details or data that aid the readers to better understand the published works and should not significantly or substantially alter the original ideas of the works.
Every Tumor Discovery submission will be pre-screened by the editors to ensure its adherence to the scope, policies and style of the journal prior to peer review. Author(s) may suggest up to 4 academically qualified reviewers for consideration per submission. Authors should insert the current contact details, including full name, email address and affiliation, of the reviewers, and state the reason(s) for recommendation in the cover letter. However, the editorial team strives to ensure that the peer review process is fair and unbiased; therefore, there is no guarantee that a recommended reviewer will be approached to perform the peer review. In addition, author(s) may indicate the name of individuals that should not be invited as peer reviewer and provide the reasons in the cover letter.
Editor-in-Chief will decide on the submissions that should be considered for publication, and assign reviewers from inside the editorial board or outside, depending on the topic, to initiate double-blind peer review. Based on the review reports and reviewers’ recommendations, Editor-in-Chief makes one of the following editorial decisions: accept, minor revision, major revision, and reject.
If the decision made necessitates minor revisions to the paper, author(s) should spend no more than 7 days to prepare and submit the revision file containing revised manuscript, title page and back matter, cover letter, and response/rebuttal letter. If the decision made necessitates major revisions to the paper, author(s) should spend no more than 30 days to prepare and submit the revision file. The revision file will be once again pre-screened by editor and subsequently reviewed by the assigned reviewers.
The peer review process is considered complete for a submission once it has been accepted for publication in Tumor Discovery. Only accepted papers will be arranged for copy-editing, typesetting and proofreading before being published online.
This journal provides immediate open access to its content on the principle of making research freely available to the public in support of a greater global exchange of knowledge.
Authors should read the “Author Guidelines” before making a submission, and make sure that the manuscripts are written in accordance with the style and specifications of Tumor Discovery.
All submissions to Tumor Discovery are subject to rigorous peer review. Prior to the peer review process, all manuscripts will be pre-screened for conformity with the theme and scope of the journal, significance of the work (and novelty for original research article), and language used.
All submissions, accessory files, article metadata and author metadata will be treated confidential. The manuscripts will only be disclosed to editorial staff, reviewers and editors who participate in the pre-screening, review, processing and preparation of the manuscript for publication.
A paper would not be considered for publication in Tumor Discovery if it has been published or is currently under consideration for publication in other journals. In the cover letter, authors must confirm and state that neither the manuscript nor any significant part of it is under consideration for publication elsewhere or has appeared elsewhere in a manner that could be construed as a prior or duplication of the same work. The authors are required to notify the editorial team if the findings and data in their submissions have been presented in conferences.
Tumor Discovery requests all members involved in the journal editing and publishing process to adhere to the Core Practices on publication ethics and follow the guidelines on handling publishing ethics allegations stipulated by Committee on Publication Ethics (COPE)
The journal strictly adheres to the guidelines and best practices, which include Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals from the International Committee of Medical Journals Editors (ICMJE) and Principles of Transparency and Best Practice in Scholarly Publishing developed by Committee on Publication Ethics (COPE), Directory of Open Access Journals (DOAJ), Open Access Scholarly Publishers Association (OASPA) and World Association of Medical Editors (WAME).
The journal editors take all possible misconducts seriously. The editors, authors or readers can forward their concerns to the journal if they find out that the description in a submission or a published article may constitute an academic fraud, research misconduct or publication malpractice. The concerns or complaints on the possible allegations submitted to the journal will be dealt with promptly and appropriately. The complainant may direct all inquiries and correspondence to the Publisher at email@example.com.
The editors do not approve of any plagiarism attempts. Duplication checker will be utilized at the editor’s discretion to verify the originality of submissions. A submission will be desk-rejected (during submissions stage) or rejected (during peer review stage) if the paper contains apparent and significant amount of plagiarized content. Therefore, authors are advised to adhere to the contemporary rules in academic writing and publishing ethics.
Tumor Discovery adopts a zero-tolerance policy concerning any academic misconducts and ethical violations in research and publication regardless of the severity of these issues. The violations include plagiarism, falsification of research, data fabrication, submitting manuscripts of others as one’s own, submitting same manuscript to different publication venues at the same time, and breached intellectual property rights. In cases of suspected misconduct and ethical violation, a panel will be formed to investigate the allegation. If the allegation is supported by evidence, the submitted manuscript in question will be declined for consideration in the journal and all authors will be informed in this regard. A retraction initiated by authors or by the journal is required to take place if the paper has already been published, and a retraction note will be published. Authors of the work in question will receive the Panel’s Decision via email and all appeals regarding the decision will have to be made to the Publisher at firstname.lastname@example.org within 28 days of the decision date.
Authors are permitted to post their non-peer-reviewed original research manuscripts to any preprint servers before or in parallel with the formal submission to Tumor Discovery, as long as the preprint is not shared under any exclusive or restrictive license. During submission, authors are obliged to declare in the cover letter if the corresponding preprint version of their submission has been deposited on a preprint server, and provide any associated accession numbers or DOIs. Preprint versions that have been shared on a preprint server will not count as prior publication.
Authors are not allowed to post any versions of articles that have been revised after peer review, accepted for publication or published in the journal on a preprint server. A submission will not be considered by Tumor Discovery if its corresponding preprint version has been indexed.
Tumor Discovery reserves the right not to consider for publication or publish material that has been formally published in digital media that shall not be construed as preprint servers.
We encourage formal citation of preprints in the reference list, where appropriate.
8. Authorship and Author Information
Authorship should be limited to individuals who have contributed substantially to the work; for instance, conception or design of the work or the acquisition, analysis, or interpretation of data for the work. Authors must indicate their specific contributions to the published work under the “Author Contribution” section. The Author Contributions section must be presented in original research articles and review articles. Refer to the author contribution part of the Instructions for Authors for more information.
Corresponding author(s) should be clearly indicated with asterisk (*) on the title page of every submission. We suggest no more than 2 corresponding authors per submission. A corresponding author is responsible for:
- obtaining permission to submit and revise paper from all the authors mentioned in the manuscript,
- ensuring adherence to all editorial and submission policies and for any communications and actions that may be necessary after publication, and
- including written permission from the authors of the work concerned for any mention of any unpublished material included in the manuscript, e.g., data from manuscripts-in-press, personal communication, or work in preparation.
Authors that made equally significant contributions to the submitted work should be clearly indicated with superscript dagger symbols (†). The following footnote should be used for authors who have made equal contributions, and placed beneath the affiliation part:
“ †These authors contributed equally to this work.” The names of all equally contributing authors are preferably indicated together in the foremost part of the authorship list, and ideally, there should be no more than 2 equally contributing authors.
Accurate and complete author information, including full name, affiliation, email address, must be disclosed and provided during submission. Affiliations should contain the following core information: department, institution, city, state, postal code, and country.
The Editorial Office of Tumor Discovery considers the authorship list is definitive by the time the submission is received. Thus, authors should check the list and order of authors before submitting their papers.
Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript is accepted for publication. The corresponding author should provide the valid reasons for the change in authorship list and the proof of written confirmation from all authors agreeing with such change (including the existing authors, author(s) to be added and/or removed) to the Editorial Office.
The requests for authorship changes need to be approved by the Editorial Office before any changes can be made.
If any requests to add, delete, or rearrange author names in the published article is granted following the finalized (online) publication of an accepted manuscript, the new changes will only be implemented in a correction (corrigendum or erratum).
At the time of submission, authors must declare any (potential) conflicts or competing interests with any institutes, organizations or agencies that might influence the integrity of results or objective interpretation of their submitted works. Conflicts of interest can be divided into two categories: financial and non-financial.
Authors should declare financial conflict of interest based on the following aspects:
- Author relation with the funding body and any potential conflicts of interest should be declared if the organization may gain or lose financially through the article publication. Disclosure should also include all sources of revenue paid (or promised to be paid) directly to authors or their institution on authors’ behalf over the 36 months before submission of the relevant work.
- Any changes to the employment status of authors in any organizations, including resignation, current employment in another organization, and anticipated employment, should be declared if the organization may gain or lose financially through the article publication.
- Ownership of stocks or shares by the authors in any organizations should be declared if author(s) may gain or lose financially through the article publication.
- Receiving consultation fees or other forms of remuneration (including reimbursements for attending conferences) from organizations should be declared if the organization may gain or lose financially as a result of article publication.
- Status of patents or patent applications (either awarded or pending) filed by the authors or their institutions should be declared if their value may be influenced by the article publication. Patent application number, patent applicant, name of inventor(s), application status, and specific aspect of paper covered by the patent application’s specification and/or claims should be disclosed.
Authors, reviewers and editors should declare any (potential) non-financial conflicts of interest and declare any unpaid roles or relations that may influence the decision on the article publication. This includes, but is not limited to, unpaid role in a government or non-governmental organization, unpaid role in an advocacy or lobbying organization, and unpaid advisory position in a commercial organization.
Authors who have nothing to declare are encouraged to add "No conflict of interest was reported by all authors" in this section of the paper. Failure to declare will result in a delay to editorial process and peer review progress. If necessary, the initial disclosure statement provided by the authors will be subject to edits for grammar corrections by the editors. Failure to comply with the conflict of interest disclosure statement requirement may result in rejection of the submissions.
In addition, reviewers and editors must disclose any association that poses a conflict of interest in connection with the manuscript. Examples of such activities could include personal or work-related relationships, events, etc.
(The explanation about financial conflicts of interest is adapted from https://www.nature.com/nature-portfolio/editorial-policies/competing-interests)
All submissions must be written entirely in good American English. Spelling and use of punctuations should conform to conventions in American English. Clarity and conciseness are critical requirements for publications; therefore, submissions that are not clearly written will be returned to authors. Authors are encouraged to employ the use of English editing service to polish and edit their papers so that they are submit-ready or publish-ready. The articles published in Tumor Discovery are in adherence with the publishable standards of academic and scientific writing.
Please note that utilizing a language editing service is not a guarantee of acceptance.
If human subjects were used in the experiments, authors must identify the committee or organization (e.g., author’s Institutional Ethics Review Board) approving the experiments in the Materials and Methods section of the manuscript, which should also detail ethics approval information such as the name of the granting committee or organization and the approval identifiers, i.e., reference numbers. Tumor Discovery requires that authors provide a proof of research ethics or ethics statement along with the submission. In the case that ethics approval identifiers are not available, written approval from the granting committee or organization must be provided as confidential supplementary file.
In the manuscript, include a statement in the Materials and Methods section confirming that the experiments were carried out in adherence to the ethical principles set out in the WMA Declaration of Helsinki or other relevant institutional and national guidelines and regulations, and that informed consent was obtained from all human subjects. For investigations undertaken on human subjects, the manner in which the informed consent was obtained from the study participants (i.e., oral or written) should be stated clearly as well.
The authors should inform the study participants of the purpose(s) of publication, the possible risks and benefits as a result of the experiment, and the patient's right to withhold or withdraw consent. Consent should be obtained from the parent(s) or legal guardian(s) if the study participant is a minor.
Authors are obliged to declare and clearly specify any restrictions on the availability or the use of human data in the manuscript.
13. Patient Anonymity and Privacy
Human subjects have a right to privacy that should not be violated without informed consent. Identifying information or patient identifiers, including patient names, initials, date of birth, contacts, medical record numbers, hospital numbers, and geographical location, should not be published in written descriptions, photographs, or pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Efforts must be made by the authors to at least mask or conceal any identifying information of the patients that appear in writing or within photograph.
Authors are obliged to explain to the patient if revealing the patient’s identity cannot be fully avoided, e.g., an image of an identifiable body part like the face has to be published in the report. The relevant identifying information to be published, e.g., the image, must be shown to the patient, and consent for publication taken for the use of that information in the publication. If the patient dies, then consent must be obtained from next of kin or legal representative. Authors may consider using our sample Consent Form for Publication in Tumor Discovery. Tumor Discovery shall consider author version of consent form for publication if all the essential items as shown in our sample consent form were included.
All submissions will be checked for documentation of patient consent for publication and for any potentially identifying information. Submissions that include identifying patient information without appropriate patient consent will not be considered for publication.
Refer to ICMJE Privacy and Confidentiality guidelines for more information about patient anonymity and privacy.
For studies describing testing on regulated animals (i.e., all live vertebrates and/or higher invertebrates), authors must identify the committee or organization (e.g., author’s Institutional Ethics Review Board) approving the experiments in the Materials and Methods section of the manuscript, which should also detail ethics approval information such as the name of the granting committee or organization and the approval identifiers, i.e., reference numbers. For research conducted on non-regulated animals, a statement should be made as to why ethical approval was not required. Tumor Discovery requires that authors provide a proof of research ethics or ethics statement along with the submission. In the case that ethics approval identifiers are not available, written approval from the granting committee or organization must be provided as confidential supplemental file.
Authors are encouraged to follow the ARRIVE guidelines while reporting animal research. In the manuscripts, any additional guidelines for the care and use of laboratory animals that were used in the experiment should be indicated. Briefly, the authors should also include animal details (e.g., species, gender, age, weight), animal housing conditions and husbandry information, and relevant steps taken to ameliorate pain and suffering of the animals in the Materials and Methods section.
Specifically, experiments on non-human primates must be performed in accordance with the recommendations set out in the Weatherall report (The Use of Non-Human Primates in Research)
To ensure research reproducibility, authors must declare what cell lines were used in their experiment and the source or origin of all cell lines utilized. It is advisable to provide information regarding the authentication of cell lines and testing for mycoplasma contamination.
Generation of de novo cell lines derived from human tissue must be approved by the relevant ethics committee (or author’s Institutional Ethics Review Board). Authors must identify the committee or organization (e.g. author’s Institutional Ethics Review Board) approving the experiments in the Materials and Methods section of the manuscript, which should also detail ethics approval information such as the name of the granting committee or organization and the approval identifiers, i.e., reference numbers. Tumor Discovery requires that authors provide a proof of research ethics or ethics statement along with the submission. In the case that ethics approval identifiers are not available, written approval from the granting committee or organization must be provided as confidential supplementary file. Authors must confirm that they obtained the consent from the donor or next of kin for deriving a cell line from the donor.
All submissions describing human and/or animal research will be preliminarily examined by journal editors to ensure that the specific requirements set out in the journal policies and guidelines are met. Submissions that do not meet the requirements may be rejected.
Tumor Discovery reserves the right to decline submissions that the editors believe the described works have not been conducted to the highest possible ethical standards, despite formal ethics approval has been obtained.
If ethical concerns arise or are discovered after publication, investigations will be organized. Any evidence pointing to substantial violations of ethical codes or oversight for the research may lead to a correction (e.g., erratum, corrigendum) or retraction of the paper. Authors’ institution, ethics committee or other appropriate body in relation to the potential ethical concerns may be contacted during the investigation.
The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.
Tumor Discovery publishes accepted manuscripts under Creative Commons Attribution 4.0 International License (CC BY 4.0). Authors who submit their papers for publication by Tumor Discovery agree to have the CC BY 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for any purpose, including commercial use, as long as the author and original source is properly cited, anyone may copy, redistribute, reuse and transform the content.
Reuse of Tumor Discovery article content
Anyone is free to reuse Tumor Discovery article content licensed under CC BY 4.0 provided that proper attribution is given through citation of the original source.
Reuse of licensed material published in another journal or book (third-party content)
Authors who submit to Tumor Discovery are responsible in obtaining permissions from the copyright owner, e.g., original publisher or authors, to reuse or republish any previously published text, figures, tables, Supplementary Information, etc., in an article of Tumor Discovery that is licensed under a CC BY 4.0 license. The official and written proof of permission must be provided along with submission, and include in the cover letter a summary regarding the licensed materials that are reused in the paper (e.g., materials that require permission and those that do not if they were published under an unrestrictive license). Upon obtaining the permission, authors should also give proper attribution as per the copyright owner’s style.
It is important to note that there is a range of Creative Commons licenses with terms that cater to different needs of copyright owners. In general, if the material was published under a CC BY license or another license that permits free and unrestricted use, the material may be reused in Tumor Discovery paper as long as proper attribution is given by citing the original source. Another example is Creative Commons Attribution-NoDerivatives License (CC BY-ND) that allows redistribution of the content, even commercially, provided that the content is reused in its entirety. Nevertheless, contact the copyright owner if you have any questions about the license terms because the editors of Tumor Discovery cannot give any professional and legal advice regarding the rights to use third-party content.
Authors are not allowed to use any third-party content in Tumor Discovery articles if written permission to reuse is not obtained from the copyright owner. In the absence of official documentation granting permission to reuse third-party content or when concerns about copyright, license or permissions arise, the editors of Tumor Discovery reserve the right to remove any third-party content from any article, whether before or after publication.
All advertisements are subject to approval of the Publisher. Advertisements must comply with the relevant regulations in the country where the advertisements appear. For more inquiries, please send email to email@example.com.
Tumor Discovery aims to be indexed by world-recognized databases, for example, Scopus, Science Citation Index (SCI) and PubMed.
Archiving Service (Archives)
The contents of Tumor Discovery will be archived and preserved by Portico.
Tumor Discovery is not liable to the statements, perspectives, and opinions contained in the published articles. The appearance of advertisements in the journal shall not be construed as a warranty, endorsement, or approval of the products or services advertised and/or the safety thereof. Tumor Discovery and the Publisher disclaim responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.